MD Anderson researchers find SABR may work better than surgery for some NSCLC patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at MD Anderson Cancer Center demonstrated that stereotactic ablative radiotherapy was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer and generated minimal side effects. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login